CN118105237A - Method, device and application for thickening choroid film thickness - Google Patents
Method, device and application for thickening choroid film thickness Download PDFInfo
- Publication number
- CN118105237A CN118105237A CN202311730954.3A CN202311730954A CN118105237A CN 118105237 A CN118105237 A CN 118105237A CN 202311730954 A CN202311730954 A CN 202311730954A CN 118105237 A CN118105237 A CN 118105237A
- Authority
- CN
- China
- Prior art keywords
- light
- choroid
- thickening
- thickness
- solar spectrum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000003161 choroid Anatomy 0.000 title claims abstract description 39
- 238000000034 method Methods 0.000 title claims abstract description 30
- 230000008719 thickening Effects 0.000 title claims abstract description 29
- 238000001228 spectrum Methods 0.000 claims abstract description 47
- 230000004379 myopia Effects 0.000 claims abstract description 22
- 208000001491 myopia Diseases 0.000 claims abstract description 22
- 210000001508 eye Anatomy 0.000 claims description 25
- 238000000295 emission spectrum Methods 0.000 claims description 17
- 238000005286 illumination Methods 0.000 claims description 17
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 5
- 229910005534 GaO2 Inorganic materials 0.000 claims description 4
- 208000022873 Ocular disease Diseases 0.000 claims description 4
- QZQVBEXLDFYHSR-UHFFFAOYSA-N gallium(III) oxide Inorganic materials O=[Ga]O[Ga]=O QZQVBEXLDFYHSR-UHFFFAOYSA-N 0.000 claims description 4
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 3
- 229910052805 deuterium Inorganic materials 0.000 claims description 3
- 229910052724 xenon Inorganic materials 0.000 claims description 3
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 claims description 3
- 201000009487 Amblyopia Diseases 0.000 claims description 2
- 229910003371 Ba2In2O5 Inorganic materials 0.000 claims description 2
- 229910002331 LaGaO3 Inorganic materials 0.000 claims description 2
- 229910012524 LiScO2 Inorganic materials 0.000 claims description 2
- 229910017848 MgGa2O4 Inorganic materials 0.000 claims description 2
- 229910015667 MoO4 Inorganic materials 0.000 claims description 2
- 238000009098 adjuvant therapy Methods 0.000 claims description 2
- 230000001186 cumulative effect Effects 0.000 claims description 2
- 230000003203 everyday effect Effects 0.000 claims description 2
- 238000005516 engineering process Methods 0.000 abstract description 6
- 238000009833 condensation Methods 0.000 abstract description 4
- 230000005494 condensation Effects 0.000 abstract description 4
- 238000004880 explosion Methods 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 4
- 230000012010 growth Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- 208000004350 Strabismus Diseases 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 229930003347 Atropine Natural products 0.000 description 3
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 3
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 3
- 229960000396 atropine Drugs 0.000 description 3
- 230000004329 axial myopia Effects 0.000 description 3
- 210000004087 cornea Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 210000001525 retina Anatomy 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- 210000003786 sclera Anatomy 0.000 description 3
- 238000007493 shaping process Methods 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 240000002329 Inga feuillei Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000001775 bruch membrane Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000003569 Central serous chorioretinopathy Diseases 0.000 description 1
- 208000024304 Choroidal Effusions Diseases 0.000 description 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 241001048891 Jatropha curcas Species 0.000 description 1
- 208000024080 Myopic macular degeneration Diseases 0.000 description 1
- 230000008572 axis elongation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000008822 capillary blood flow Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000004515 progressive myopia Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
Landscapes
- Radiation-Therapy Devices (AREA)
Abstract
The invention relates to the fields of photo-bioelectronics, medical equipment, advanced treatment technology, myopia prevention and control and treatment, and particularly discloses a method, a device and application for thickening choroid thickness, wherein the method utilizes artificial light simulating solar spectrum configuration under tree shadow to illuminate the fundus for thickening the choroid thickness; the wavelength of the artificial light is in the range of 550-1100nm. The method for thickening the choroid film thickness provided by the invention simulates artificial light of a solar spectrum configuration under tree shade to illuminate the fundus, can effectively increase the choroid film thickness, improve myopia and reduce the refractive index, and simultaneously, by using natural light, the method is safer to use without explosion ionization and light condensation caused by strong pulse light.
Description
Technical Field
The invention relates to the fields of photo-bioelectronics, medical equipment, advanced treatment technology, myopia prevention and control and treatment, in particular to a luminous device for thickening choroid thickness and application thereof.
Background
The choroid is the main vascular tissue of the fundus, is positioned between the retina and the sclera, plays a main role in providing nutrition and oxygen for the retina, and also plays roles in absorbing light, regulating body temperature, regulating intraocular pressure and the like. Histologically, the choroid of most species is divided into five layers, the Bruch's membrane, capillary layer, medium vascular layer, large vascular layer and suprachoroidal space in that order from the retinal side. In addition to Bruch membranes, the other layers are mainly blood vessels (International journal of ophthalmology, 2022, 3, vol.22, 3, 407-411). In recent years, choroid thickness becomes an important marker for myopia research, and choroid thickness change and mechanism thereof are one of main directions for myopia pathological mechanism research.
Studies have shown that there is a significant negative correlation between choroidal thickness and myopic power, with increasing choroidal thickness being expected to inhibit the increase in myopic refractive index and the occurrence of high myopic complications (Chinese strabismus and pediatric journal of ophthalmology, 2023,31 (3), 30-33). When the eye axis elongation speed exceeds the normal physiological speed of human body, the rapid elongation compression of the eye axis leads to the thinning of the choroid membrane thickness, the reduction of choroidal blood flow, the reduction of choroidal capillary blood flow perfusion, the increase of the area of the capillary blood vessel layer blood flow free area, the further caused ischemia and hypoxia of sclera and the thinning of sclera further aggravate the axial elongation of eyeball, so that the circulation accelerates the myopia progression (Chinese strabismus and pediatric ophthalmic journal, 2023,31 (3), 30-33). Stone et al found that both latent myopic children and normal children exhibited a non-uniform thinning trend in the macular area choroidal thickness during the 1 year follow-up, with the former thinning being more severe than the latter (new ophthalmic progression, 2023,43 (11), 877-881). From this point of view, early screening by a combination of ocular axis length and choroidal thickness changes helps to discover latent myopia and early intervention in children. In highly myopic patient populations, it was found that macular choroidal thinning exacerbates complications such as myopic macular degeneration, choroidal neovascularization, central serous chorioretinopathy (university of science and technology, national institute (medical edition), 20221,50 (6), 793-799).
Illumination is one of the effective ways to increase choroidal thickness, but not all illumination can increase choroidal thickness. Scott a.read et al found that choroidal thickening was evident using the adult healthy population study model with solar continuous treatment for 7 days in the morning before 9 days for 30 minutes per day (SCIENTIFIC REPORT,2018,8,8200). Jaemoon Ahn et al follow-up for 27 men for one week, with exposure to 150lux of weak light before 8 spots per night for the first 2 days, then exposure to 1000lux of strong light after 8:00 a night to pre-sleep for 5 consecutive days, and found that exposure to 1000lux of strong light for 5 consecutive days before sleep was significantly thinner in choroidal membrane thickness than 150lux of weak light for the first two days (Experimental EYE RESEARCH,2017,164,157-167). It was found that the retinal and choroidal structures and functions of myopic eyes were significantly altered, and that the reduced thickness of the retina, tissue loss, reduced vascular branching complexity, and reduced vascular density could be related to insufficient nutrient and oxygen supply due to reduced choroidal thickness (international journal of ophthalmology 2022, 3, 22, 3 rd edition, 407-411), but it was not denied that reduced retinal thickness could be related to ultraviolet, near ultraviolet, and visible light-induced fluorescent damage.
The latest technologies for preventing and controlling myopia in recent years mainly comprise the steps of wearing a cornea shaping lens, titrating low-concentration atropine and using a nursing light instrument for 650nm laser irradiation, and find that effective measures for preventing and controlling myopia are taken in clinical researches, wherein the measures comprise the adoption of the low-concentration atropine (new development of ophthalmology, 2023,43 (11), 887-892, chinese strabismus and pediatric ophthalmic journal, 2023,31 (3), 30-33), a nursing light instrument (RLRL) (international ophthalmic journal, 2023,23 (5), 791-796, chinese strabismus and pediatric ophthalmic journal, 2023,31 (3), 30-33) and cornea shaping lens (clinical and education of general medicine, 2021,10,910-913; university of medical science, 2019,48 (9), 822-827) and the phenomenon of choroid thickening of myopic patients. However, the cost of wearing the cornea shaping lens is high, and the lens needs to be continuously replaced along with the growth of children and teenagers; the low-concentration atropine cannot be continuously used for many years; there is a certain potential safety hazard for laser.
Based on the technical background, the invention provides a method, a device and application for thickening the choroid thickness.
Disclosure of Invention
Aiming at the defects of the prior art, the invention provides a method, a device and application for thickening the choroid thickness, which simulate artificial light with a solar spectrum configuration under tree shade to illuminate the fundus, can effectively increase the choroid thickness, delay and inhibit the growth of an eye axis, improve myopia, reduce the refractive index and improve vision, and simultaneously, the method is safer to use by using natural light without explosion ionization and light condensation caused by strong pulse light.
To achieve the above object, a first aspect of the present invention provides a method of thickening choroidal thickness by illuminating the fundus with artificial light simulating a solar spectrum configuration under shade of a tree for thickening choroidal thickness;
The wavelength of the artificial light is in the range of 550-1100nm.
The second aspect of the present invention provides a device used in the method, where the device is an LED lighting device, or a wavelength filtered xenon lamp light source, or a wavelength filtered deuterium lamp light source.
In a third aspect the invention provides the use of the device described above for thickening choroidal space, for the preparation of a medical device or medical device using the device as a core light emitting component.
The technical effects of the invention include:
(1) According to the method for thickening the choroid film, disclosed by the invention, artificial light with a solar spectrum configuration under tree shade is simulated to illuminate the fundus, so that the choroid film thickness can be effectively increased, myopia is improved, the refractive index is reduced, and the vision is improved.
(2) According to the method for thickening the choroid film, artificial light with the wavelength range of 550-1100nm is adopted to illuminate the fundus, so that the growth of the ocular axis can be delayed and inhibited, the potential safety hazard of the existing myopia prevention and control means is avoided, and a new thought is provided for preventing and controlling the myopia of teenagers.
Additional features and advantages of the invention will be set forth in the detailed description which follows.
Drawings
The foregoing and other objects, features and advantages of the invention will be apparent from the following more particular descriptions of exemplary embodiments of the invention as illustrated in the accompanying drawings wherein like reference numbers generally represent like parts throughout the exemplary embodiments of the invention.
FIG. 1 is a graph showing the comparison of chemical and thermal hazard values of solar spectrum and solar spectrum under shade and different wavelengths of light in one embodiment of the method for increasing choroidal thickness according to the present invention.
FIG. 2 is a graph showing the emission spectrum of an LED device encapsulated with YAl 3(BO3)4:Cr3+ phosphor and its comparison with the solar spectrum and the solar spectrum under shade in another embodiment of the method of increasing choroidal thickness according to the present invention.
Fig. 3 is a schematic diagram showing the emission spectrum of an LED device encapsulated with SrGa 12O19:Cr3+ phosphor and its comparison with solar spectrum and solar spectrum under shade in another embodiment of the method for thickening choroid according to the present invention.
FIG. 4 is a graph showing the emission spectrum of an LED device encapsulated with Al 2P6O18:Cr3+ phosphor and the comparison of the LED device with the solar spectrum and the solar spectrum under shade in another embodiment of the method for increasing the thickness of the choroid according to the present invention.
Fig. 5 is a schematic diagram showing the emission spectrum of an LED device encapsulated with InGa 3O6:Cr3+ phosphor and its comparison with solar spectrum and solar spectrum under shade in another embodiment of the method of thickening choroid according to the present invention.
FIG. 6 is a graph showing the emission spectra of an LED device encapsulated with YAl 3(BO3)4:Cr3+ and LiScSi 2O6:Cr3+ phosphors and its comparison with the solar spectrum and the solar spectrum under shade in another embodiment of the method of increasing choroidal thickness according to the present invention.
Fig. 7 is a graph showing statistical mean versus variance of choroidal thickness of control and CNC groups obtained by detecting 30 samples per group every 3 months over a period of 12 months in a third embodiment of the proposed method of thickening choroidal thickness.
Fig. 8 is a graph showing statistical mean value versus variation of eye axis lengths of control and CNC groups obtained by detecting 30 samples per group every 3 months over a period of 12 months in a fourth embodiment of the proposed method for thickening choroid thickness.
Fig. 9 is a graph showing the comparison of the statistical average value and the variation of refractive power of the control group and the CNC group, which are obtained by detecting 30 samples per group every 3 months for a period of 12 months in the fifth embodiment of the method for thickening choroid according to the present invention.
Detailed Description
Preferred embodiments of the present invention will be described in more detail below. While the preferred embodiments of the present invention are described below, it should be understood that the present invention may be embodied in various forms and should not be limited to the embodiments set forth herein.
In the present invention, unless otherwise indicated, terms of orientation such as "upper and lower" are used to generally refer to the upper and lower portions of the device in normal use, and "inner and outer" are used with respect to the profile of the device. Furthermore, the terms "first, second, third and the like" are used for descriptive purposes only and are not to be construed as indicating or implying a relative importance or implicitly indicating the number of technical features indicated. Thus, a feature defining "a first, second, third" may explicitly or implicitly include one or more such feature. In the description of the present invention, the meaning of "a plurality" is two or more, unless explicitly defined otherwise.
The invention provides a method for thickening choroid film thickness, which uses artificial light simulating solar spectrum configuration under tree shade to illuminate the eye bottom for thickening choroid film thickness;
the wavelength of the artificial light is in the range 550-1100nm.
According to the invention, artificial light simulating solar spectrum configuration under shade is used for illuminating the bottom of the eye, so that the choroid thickness can be effectively increased, myopia is improved, the refractive index is reduced, the vision is improved, and meanwhile, by using natural light, explosion ionization and light condensation caused by strong pulse light are avoided, so that the use is safer.
According to the invention, the artificial light adopts intermittent illumination, enters the fundus through direct irradiation or reflection, and the illumination time of two adjacent times is not shorter than 45 minutes; each continuous illumination lasts no more than 30 minutes; each time the irradiation quantity of the light to the eyes is 0.01-3J/cm 2, the cumulative irradiation quantity of the light to the eyes is not more than 10J/cm 2 every day.
Preferably, each continuous illumination time is 5-15 minutes.
According to the invention, artificial light with the wavelength range of 550-1100nm is adopted to illuminate the eye bottom, so that the growth of the eye axis can be delayed and inhibited, the potential safety hazard existing in the existing myopia prevention and control means is avoided, and a new thought is provided for preventing and controlling the myopia of teenagers.
The second aspect of the present invention provides a device used in the method, where the device is an LED lighting device, or a wavelength filtered xenon lamp light source, or a wavelength filtered deuterium lamp light source.
According to the invention, the device is an LED lighting device;
the LED light emitting device includes:
An LED blue light chip;
and the red light-near infrared fluorescent powder is packaged with the LED blue light chip.
According to the invention, the peak value of the emission wavelength of the LED blue light chip is 440-480nm, preferably 471nm, and the half-width of the emission spectrum is not more than 25nm.
According to the present invention, the red-near infrared phosphor includes at least one of ABO3:Cr3+、Ln(Al,Ga,Sc)3(BO3)4:Cr3+、(Li,Na)(Ga,Sc)O2:Cr3+、Ga2O3:Cr3+、MD2O4:Cr3+、MgGaBO4:Cr3+、MAl12O19:Cr3+、D(PO3)3:Cr3+、(Al,Sc,Ga)2P6O18:Cr3+、D2(WO4)3:Cr3+、Ba3In2WO9:Cr3+、Ba2In2O5:Cr3+、(Y,Gd)3(Ga,Sc,Al)5O12:Cr3+,Mg4Nb2O9:Cr3+、(Li,Na,K)ScSi2O6:Cr3+、Li(Sc,Al,Ga)O2:Cr3+、(Sr1-xBax)Ga12O19:Cr3+(x≤0.1)、In(GaO2)3:Cr3+、Zn4InGaO7:Cr3+、Zn3In2O6:Cr3+、In3Sb5O12:Cr3+、GdYScSbO7:Cr3 +、GaSbO4:Cr3+、In2(MoO4)3:Cr3+、K3ScSi2O7:Eu2+;
Wherein A and Ln are each independently any one of Y, la, ce, pr, sm, eu, gd, tb, dy, ho, er, tm, yb, lu;
b is Sc or Ga;
m is any one of Mg, ca, sr, ba;
d is any one of Al, ga, sc, in.
Preferably, the red-near infrared phosphor includes at least one of YAl3(BO3)4:Cr3+、MgGa2O4:Cr3+、LaGaO3:Cr3+、Ga2O3:Cr3+、Gd3Ga5O12:Cr3+、SrGa2O19:Cr3+、YGa3(BO3)4:Cr3+、Al(PO3)3:Cr3+、GdScO3:Cr3+、LiScSi2O6:Cr3+、LiScO2:Cr3+、In(GaO2)3:Cr3+ and Ce (Sc, ga) 3(BO3)4:Cr3+.
The invention also provides an application of the device in thickening the choroid thickness, wherein the application is to prepare medical equipment or medical equipment by using the device as a core luminous component.
Preferably, the use is as a treatment or adjuvant treatment for ocular diseases associated with choroid thickness;
Ocular diseases associated with choroidal thickness include myopia and amblyopia.
The present invention will be described in more detail with reference to the following examples.
Example 1
The embodiment provides comparison of chemical hazard and thermal hazard values of solar spectrum and solar spectrum under shade and different wavelengths of light, and is used for providing reference data for a method for thickening choroid film thickness;
To determine the spectral configuration, spectra under the sun and under the shade were collected and compared; the spectrum is collected in Tunxi paths 193 of the joint fertilizer industry university campus of Anhui province by using a light spectrum illuminance analyzer with the model number OHSP-350S manufactured by Hangzhou iridescent light spectrum light color science and technology limited company on 5-6 days of 2021, wherein one condition is on the grasslands of an open basketball court, and the other condition is under the jatropha curcas on the roads between the basketball court and a football court, and the collected spectrum distribution is shown in the figures 1 (a and b) respectively; it can be seen that there is a significant difference in the spectrum under tree shade and under non-tree shade, especially in the 700-750nm segment; as can be seen from comparison of the chemical hazard (B) and the thermal hazard (R) of the light in FIG. 1c, the present invention uses light in the wavelength range of 600-1100nm, especially 650-950nm, without chemical hazard; although light in the 600-700nm range is slightly thermally compromised, and the thermal hazard gradually decreases as the wavelength increases; in coping with thermal hazards, the present invention can be overcome by intermittent illumination.
Example 2
The embodiment is realized by utilizing the technical scheme of matching the LED blue light chip with the fluorescent powder for the solar spectrum under the shade shown in the embodiment 1, wherein certain single fluorescent powder can be adopted, a mode of mixing a plurality of fluorescent powders can be adopted, a section of the solar spectrum under the shade can be simulated, and a wider wavelength range can be covered;
FIG. 2 shows the emission spectrum of an LED device packaged by YAl 3(BO3)4:Cr3+ fluorescent powder and the comparison of the emission spectrum with the solar spectrum (a) and the solar spectrum (b) under shade, and it can be seen that the emission spectrum of the device covers the junction of the solar spectrum in the visible band of 600-850nm and the near infrared solar spectrum under shade better;
FIG. 3 shows the emission spectrum of an LED device encapsulated by SrGa 12O19:Cr3+ fluorescent powder and the solar spectrum (a) and the sun under tree shade, and it can be seen that the device emission spectrum covers the initial part of the near infrared solar spectrum under the tree shade of 600-900 nm;
FIG. 4 shows the emission spectrum of an LED device encapsulated with Al 2P6O18:Cr3+ phosphor and its comparison with the solar spectrum (a) and the shade-lower solar spectrum (b), from which it can be seen that the device emission spectrum better covers the shade-lower near infrared solar spectrum of 700-900nm, especially the 750-850nm range;
FIG. 5 shows the emission spectrum of an LED device encapsulated with InGa 3O6:Cr3+ phosphor and its pairs with solar spectrum (a) and shade-lower solar spectrum (b), from which it can be seen that the device emission spectrum better covers the shade-lower near infrared solar spectrum of 750-1050nm, especially the 800-950 nm;
Fig. 6 shows the emission spectra of LED devices encapsulated with YAl 3(BO3)4:Cr3+ and LiScSi 2O6:Cr3+ phosphors and their comparison with solar spectrum (a) and solar spectrum (b) under tree shade, from which it can be seen that the spectral configuration change of solar spectrum from visible to infrared band can be better simulated with the combination of two phosphors.
Example 3
This example provides a choroidal membrane thickness experiment:
During the period of 10 months 2021 to 4 months 2023, 60 children and teenagers are continuously tracked and observed, the observed objects are divided into two groups of 30 persons, one group uses a normal household illumination light source for life and study, namely a control group, and the other group uses red light-near infrared light shown in fig. 2 for intervention, namely a CNC group; the CNC group provides a CNC table lamp developed in the project on the basis of original household life, the lamp surface is round, the diameter is 20cm, when the distance between eyes of volunteers and the lamp surface is 10-20cm, and the irradiation intensity is 0.5-1.3mW/cm 2; the use requirement of CNC desk lamp: each day is divided into three periods of early, middle and late, and each of the morning and noon receives one illumination for 5-15 minutes each time; the red light and the white light are lighted in turn according to the red light-white light-red light-white light … red light sequence at night, the white light illumination time is set to 45 minutes each time when desk lamp illumination is used at night for working, the red light illumination is respectively received for 5-15 minutes before and after the white light illumination is received, the working amount is large, the white light illumination time is long, and the number of times of receiving the red light illumination is correspondingly large; for both the control group and the CNC group, the measured choroid thickness raw data are shown in Table 1, and the data in Table 1 are statistically analyzed to obtain the average value and the variation of the choroid thickness of the two groups of samples, which are shown in Table 2; using the left plot of the data in table 2, the trend of the change in choroid thickness over time for the two sets of samples is shown in fig. 7; as can be seen from fig. 7 in combination with the data in table 2, the choroidal thickness of the control group was gradually thinned as time elapsed, while the CNC group was not thinned as time elapsed but a significant thickening phenomenon occurred; thus, using the incoherent type of red-near infrared intervention developed by the present invention, the choroid can be thickened;
TABLE 1 choroidal thickness raw data collected for both CNC and control subjects
TABLE 2 statistical analysis of choroidal thicknesses of both CNC and control groups
Example 4
This example provides an eye axis length experiment:
This example is the same as example 3, but the monitored index data is different; in carrying out example 3, the ocular axis length was monitored simultaneously; the original data of the eye axis length measured in this embodiment are shown in table 3, and the average value and the variation of the eye axis lengths of two groups of samples obtained by performing statistical analysis on the data in table 3 are shown in table 4; using the left graph of the data in table 4, the trend of the eye axis length of the two groups of samples over time is shown in fig. 7; as can be seen from fig. 8 in combination with the data in table 4, the eye axis length of the control group increased relatively much over time, while the CNC first three replicates showed little or even slightly less, and the fourth replicates showed slightly more; the abnormal change of the fourth review is not excluded because of the false rejection of students or other external accidental factors; in general, the use of incoherent type red-near infrared light interventions developed by the present invention can effectively inhibit the ocular axis transitional growth of juvenile axial myopia.
Table 3 eye axis length raw data collected by cnc and control subjects
Table 4 statistical analysis of eye axis lengths for both cnc and control groups
Example 5
This example provides a myopic diopter experiment:
this example is the same as example 3, but the monitored index data is different. In carrying out example 3, diopters were monitored simultaneously; the diopter raw data measured in this embodiment are shown in table 5, and the average value and the variation of diopter of two groups of samples obtained by performing statistical analysis on the data in table 5 are shown in table 6; using the left plot of the data in table 6, the trend of the two sets of sample diopters over time is shown in fig. 7; as can be seen from fig. 8 in combination with the data in table 4, the diopter increase of the control group is relatively large and the myopia degree increase is obvious as time goes on, while the CNC three previous reviews have little increase, even slightly decrease, and the fourth review slightly increases; the abnormal change of the fourth review is not excluded because of the false rejection of students or other external accidental factors; in general, the incoherent red light-near infrared light intervention developed by the invention can effectively delay and inhibit the degree of the axial myopia exacerbation of the teenagers of children, and even plays a role in treating the reversion of the myopia to a certain degree.
Table 5 diopter raw data collected by two subjects in cnc and control group
/>
/>
Table 6. Analysis of refractive index statistics for both cnc and control groups
Example 1 of the present invention illustrates the technical source of the inventive concept of the present invention, using sun light under shade, giving a spectral configuration and further illustrating that the light employed by the present invention has no chemical and obvious thermal effects; example 2 illustrates that the blue LED chip and phosphor powder can simulate the required solar spectrum, which makes the technology feasible; example 3 demonstrates that the choroidal membrane thickness can be enhanced by employing the light developed in the present invention, as compared to the control group; the length of the eye axis is one of key indexes of the axial myopia, and people with higher myopic degree tend to have longer eye axis or have higher diopter of the myopia when the eye axis is longer; example 4 demonstrates that light developed using the present invention can actually delay the inhibition of the growth of the ocular axis by comparison to the control group; example 5 demonstrates that light developed using the present invention can actually improve myopia and reduce refractive index by comparison to the control.
According to the method for thickening the choroid film, disclosed by the embodiment of the invention, artificial light with a solar spectrum configuration under tree shade is simulated to illuminate the fundus, so that the choroid film thickness can be effectively increased, myopia is improved, the refractive index is reduced, and meanwhile, natural light is simulated, explosion ionization and light condensation caused by strong pulse light are avoided, so that the use is safer.
The foregoing description of embodiments of the invention has been presented for purposes of illustration and description, and is not intended to be exhaustive or limited to the embodiments disclosed. Many modifications and variations will be apparent to those of ordinary skill in the art without departing from the scope and spirit of the various embodiments described.
Claims (10)
1. A method of thickening choroid film, characterized in that artificial light simulating a solar spectrum configuration under shade is used to illuminate the fundus for thickening choroid film;
The wavelength of the artificial light is in the range of 550-1100nm.
2. The method according to claim 1, wherein the artificial light is irradiated intermittently, by direct irradiation or reflection, into the fundus, the time between adjacent irradiation being not shorter than 45 minutes; each continuous illumination lasts no more than 30 minutes; each time the irradiation quantity of the light to the eyes is 0.01-3J/cm 2, the cumulative irradiation quantity of the light to the eyes is not more than 10J/cm 2 every day.
3. The method of claim 2, wherein each continuous illumination time is 5-15 minutes.
4. A device for use in the method of any one of claims 1 to 3, wherein the device is an LED lighting device, or a wavelength filtered xenon lamp light source, or a wavelength filtered deuterium lamp light source.
5. The device of claim 4, wherein the device is an LED lighting device;
the LED light emitting device includes:
An LED blue light chip;
And the red light-near infrared light fluorescent powder is packaged with the LED blue light chip.
6. The device according to claim 5, wherein the emission wavelength of the LED blue light chip has a peak value of 440-480nm, preferably 471nm, and the half-width of the emission spectrum is not more than 25nm.
7. The device of claim 6, wherein the red-near infrared phosphor comprises at least one of ABO3:Cr3+、Ln(Al,Ga,Sc)3(BO3)4:Cr3+、(Li,Na)(Ga,Sc)O2:Cr3+、Ga2O3:Cr3+、MD2O4:Cr3+、MgGaBO4:Cr3+、MAl12O19:Cr3+、D(PO3)3:Cr3+、(Al,Sc,Ga)2P6O18:Cr3+、D2(WO4)3:Cr3+、Ba3In2WO9:Cr3+、Ba2In2O5:Cr3+、(Y,Gd)3(Ga,Sc,Al)5O12:Cr3+,Mg4Nb2O9:Cr3+、(Li,Na,K)ScSi2O6:Cr3+、Li(Sc,Al,Ga)O2:Cr3+、(Sr1-xBax)Ga12O19:Cr3+(x≤0.1)、In(GaO2)3:Cr3+、Zn4InGaO7:Cr3+、Zn3In2O6:Cr3+、In3Sb5O12:Cr3+、GdYScSbO7:Cr3+、GaSbO4:Cr3+、In2(MoO4)3:Cr3+、K3ScSi2O7:Eu2+;
Wherein A and Ln are each independently any one of Y, la, ce, pr, sm, eu, gd, tb, dy, ho, er, tm, yb, lu;
b is Sc or Ga;
m is any one of Mg, ca, sr, ba;
d is any one of Al, ga, sc, in.
8. The device of claim 7, wherein the red-near infrared phosphor comprises at least one of YAl3(BO3)4:Cr3+、MgGa2O4:Cr3+、LaGaO3:Cr3+、Ga2O3:Cr3+、Gd3Ga5O12:Cr3+、SrGa2O19:Cr3+、YGa3(BO3)4:Cr3+、Al(PO3)3:Cr3+、GdScO3:Cr3+、LiScSi2O6:Cr3+、LiScO2:Cr3+、In(GaO2)3:Cr3+ and Ce (Sc, ga) 3(BO3)4:Cr3+.
9. Use of a device according to any one of claims 4-8 for thickening choroidal membranes, wherein the use is for preparing a medical device or a medical device using the device as a core light emitting component.
10. The use according to claim 9, wherein the use is a treatment or adjuvant treatment of an ocular disorder associated with choroidal thickness;
The ocular diseases associated with choroid thickness include myopia and amblyopia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311730954.3A CN118105237A (en) | 2023-12-15 | 2023-12-15 | Method, device and application for thickening choroid film thickness |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311730954.3A CN118105237A (en) | 2023-12-15 | 2023-12-15 | Method, device and application for thickening choroid film thickness |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118105237A true CN118105237A (en) | 2024-05-31 |
Family
ID=91215089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311730954.3A Pending CN118105237A (en) | 2023-12-15 | 2023-12-15 | Method, device and application for thickening choroid film thickness |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118105237A (en) |
-
2023
- 2023-12-15 CN CN202311730954.3A patent/CN118105237A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sample et al. | Isolating the color vision loss in primary open-angle glaucoma | |
| US7524060B2 (en) | Therapeutic contact lens for pseudo-aphakic eyes and/or eyes with retinal neuro-degeneration | |
| CoLLMAN et al. | Sunlight and other risk factors for cataracts: an epidemiologic study. | |
| CN101370450A (en) | Therapeutic and prophylactic ophthalmologic lens for pseudoaphakic eyes and/or eyes undergoing a neurodegenerative process | |
| CN105204179B (en) | Eye-protecting and sleep-benefiting healthy glasses | |
| CN204925532U (en) | Sharp healthy glasses of sleeping of eyeshield | |
| Grierson | The eye book: eyes and eye problems explained | |
| CN118105237A (en) | Method, device and application for thickening choroid film thickness | |
| Van den Berg | Red glasses and visual function in retinitis pigmentosa | |
| Morse et al. | Aging and visual impairment | |
| Rosenfield | Living with blue light exposure | |
| Anduze | Ultraviolet radiation and cataract development in the US Virgin Islands | |
| CN118208683A (en) | Luminous device, method and application for inducing tear secretion to improve tear height | |
| Roberts et al. | Artificial lighting and the blue light hazard | |
| DeSchweinitz | Angioid streaks in retina | |
| CN108388027A (en) | By the method and device for filtering out the spectral component prevention and control myopia of specific wavelength | |
| GB2374428A (en) | Testing for colour preference and light sensitivity using tinted lenses | |
| CN102049101A (en) | Red filtering glasses for treating hyperopia | |
| Nacer et al. | Color vision testing in an area with high levels of ambient illumination | |
| Marcove | Engelking, E. Color iireakn& and artificial temporary co& blindness. Klin. M. f. Augenh., 1933, v. 90, Jan., I’. 9.(Ill.) Engelking retested on the anomalo | |
| Samman | VISION, DEFECTS OF | |
| Varrier | Clinical Study on the Effect of Shveta Palandu Arka Aschyothana in the Management of Kaphaja Timira (Immature Cataract) | |
| CN116099130A (en) | Light source assembly, visual physiotherapy instrument and visual physiotherapy method | |
| Ballen | Surgical treatment of intermittent exotropia | |
| Kirk Smick et al. | Blue light hazard |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication |